Clinical trial
Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer
NCT00006380 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00006380 |
|---|---|
| Title | Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer |
| Official title | Phase I Evaluation of 131I-J591 Murine Monoclonal Antibody in Patients With Progressive Androgen-Independent Prostate Cancer |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological, Radiation |
| Interventions | monoclonal antibody muJ591, iodine I 131 monoclonal antibody muJ591 |
| Start date | Sep 1, 2000 |
| Primary completion | Mar 1, 2002 |
| Completion | Mar 1, 2002 |
| First posted | Jun 9, 2004 |
| Last update posted | Jun 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: